Table 2. Diagnostic examination and treatment allocation in the research group of young patients (≤34 years old).
| Variable | 1999–2003, N (%) | 2004–2008, N (%) | *P value |
|---|---|---|---|
| Mammography | 0.309 | ||
| No | 94 (74.6) | 79 (68.7) | |
| Used | 32 (25.4) | 36 (31.3) | |
| Breast ultrasound | <0.001 | ||
| No | 78 (61.9) | 33 (28.4) | |
| Used | 48 (38.1) | 83 (71.6) | |
| MRI | 0.007 (fisher test) | ||
| No | 133 (100.0) | 132 (94.3) | |
| Used | 0 (0.0) | 8 (5.7) | |
| Breast ultrasound and mammography | <0.001 | ||
| No | 117 (92.9) | 87 (75.7) | |
| Used | 9 (7.1) | 28 (24.3) | |
| Surgery | <0.001(fisher test) | ||
| No | 4 (2.9) | 7 (4.6) | |
| Mastectomy | 31 (22.1) | 8 (5.2) | |
| Radical mastectomy | 96 (68.6) | 107 (69.9) | |
| Breast-conserving surgery | 4 (2.9) | 28 (18.3) | |
| Simple mastectomy | 3 (2.1) | 1 (0.7) | |
| Other | 2 (1.4) | 2 (1.3) | |
| Chemotherapy | 0.994 | ||
| No | 15 (10.6) | 16 (10.7) | |
| Yes | 126 (89.4) | 134 (89.3) | |
| Radiotherapy | 0.287 | ||
| No | 90 (73.2) | 94 (67.1) | |
| Yes | 33 (26.8) | 46 (32.9) | |
| Endocrine therapy | 0.211 | ||
| No | 19 (28.8) | 28 (38.9) | |
| Yes | 47(71.2) | 44 (61.1) | |
| HER-2+ targeted drug therapy | 1.000 (fisher test) | ||
| No | 12 (100.0) | 26 (96.3) | |
| Yes | 0 (0.0) | 1 (3.7) |
*, chi-square test or specified. N, patient number of each subgroup; n, sampling size; MRI, magnetic resonance imaging; HER-2, human epidermal growth factor receptor 2.